Stereotaxis (STXS) Vdrive Hits 500 Procedure Milestone
Up)
Stereotaxis, Inc. (Nasdaq: STXS) announced that its Vdrive Robotic Navigation System, which provides physicians the ability to remotely manipulate traditionally non-robotic catheters, is growing in popularity and is expected to surpass 500 clinical procedures in Europe in February. The company also announced it has received regulatory clearance from Health Canada to commercially market the device in Canada.
Since the initial product release in Europe in 2011, the Vdrive system has been installed in nine centers, with units scheduled to be installed in additional centers during the first quarter of 2012. The initial nine centers have performed 473 clinical cases with approximately 80% being completed in the left atrium of the heart.
Numerous cases have been performed with the Vdrive™ system and clinical feedback continues to be very positive," said Michael P. Kaminski, President and CEO of Stereotaxis. "With the Health Canada market clearance for the Vdrive system, and our planned new Vdrive installations in Europe and Canada this year, we are well-positioned to drive the growth and further adoption of this exciting technology in electrophysiology labs in these important markets."
In a fully remote procedure environment, the Vdrive system increases the clinical techniques available to the physician and reduces the need to re-enter the sterile field to adjust devices. Initial clinical data from European physicians demonstrates that this simplification saves 30 minutes(1) or more in robotic procedures, depending on the individual clinical technique. Furthermore, the addition of robotic diagnostic catheter manipulation is another step in Stereotaxis' vision to improve device control. Stereotaxis' broad Epoch™ solutions portfolio also includes precise magnetic control of ablation catheters with Ni
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Since the initial product release in Europe in 2011, the Vdrive system has been installed in nine centers, with units scheduled to be installed in additional centers during the first quarter of 2012. The initial nine centers have performed 473 clinical cases with approximately 80% being completed in the left atrium of the heart.
Numerous cases have been performed with the Vdrive™ system and clinical feedback continues to be very positive," said Michael P. Kaminski, President and CEO of Stereotaxis. "With the Health Canada market clearance for the Vdrive system, and our planned new Vdrive installations in Europe and Canada this year, we are well-positioned to drive the growth and further adoption of this exciting technology in electrophysiology labs in these important markets."
In a fully remote procedure environment, the Vdrive system increases the clinical techniques available to the physician and reduces the need to re-enter the sterile field to adjust devices. Initial clinical data from European physicians demonstrates that this simplification saves 30 minutes(1) or more in robotic procedures, depending on the individual clinical technique. Furthermore, the addition of robotic diagnostic catheter manipulation is another step in Stereotaxis' vision to improve device control. Stereotaxis' broad Epoch™ solutions portfolio also includes precise magnetic control of ablation catheters with Ni
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Repros Therapeutics (RPRX) Modifies Pivotal Androxal Protocol
- Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
